couter

SANASana Biotechnology, Inc.

Sana Biotechnology, Inc. (SANA) sells engineered cell therapies for autoimmune and oncologic diseases, with a focus on in vivo CAR T-cell platforms. The next catalyst is Nov 23, 2026 — SC291 Longer-Term Durability Data (ASH), which will test the durability of its lead therapy in long-term patient outcomes.

  • SANA has raised $69M through an ATM offering in May 2026, signaling short-term liquidity management.
  • The company reported a net loss of $154M in Q3 2026, with free cash flow of -$332.6M over the past 12 months.
  • Shareholders’ equity stands at $160.88M, with no clear path to profitability in the near term.

The Read

Sana Biotechnology’s stock has reacted negatively to financial updates lacking cash runway clarity and dilution fears, but surged about 64% on Q1 2026 results and strategic collaborations before falling 11.
Nov 5, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Thu5Nov

    The earnings release will test the company's ability to deliver on its financial guidance and provide clarity on its cash runway, which is critical for a small-cap biotech with limited liquidity. This differs from the last earnings print, which focused more on financing clarity than operational performance.

  • Mon23Nov

    The release of longer-term durability data will test the market's reaction to the potential of Sana's therapy in maintaining efficacy over time, which could influence investor sentiment and valuation.

  • Wed20Jan

    The initial clinical data presentation will test the market's response to early-stage results, which could impact investor confidence and the stock's valuation based on the data's strength.

  • Thu4Feb

    The earnings release will test whether Sana can deliver a guidance reset with forward-looking commentary, unlike the last print where the bearish outcome was driven by cash flow concerns.

  • Thu11Feb

    The IND and pre-clinical validation update will test the market's reaction to the progress of Sana's drug development, which could influence the stock's valuation based on regulatory and scientific advancements.

  • Thu6May

    This release will test the ability to reset guidance and re-rate the stock based on updated clinical and financial expectations, differing from the last print where the bearish outcome was tied to cash flow constraints.

  • Thu5Aug

    The earnings release will test the ability to reset guidance and re-rate the stock based on updated clinical and financial expectations, differing from the last print where the bearish outcome was tied to cash flow constraints.

  • Thu11Nov

    This release will test the ability to reset guidance and re-rate the stock based on updated clinical and financial expectations, differing from the last print where the bearish outcome was tied to cash flow constraints.

Past

  • Thu1Oct

    Actual outcome: Bear · $2.47 at outcome

    The stock fell 14.5% following the event, underscoring investor disappointment with the strategic partnership update. The announcement failed to meet expectations, with limited details on financial terms or tangible benefits, leading to a sharp decline. The price fell below the bear floor, reflecting skepticism about the partnership's impact on long-term growth and financial health.

    Potential announcement of non-dilutive capital or corporate collaboration.

  • Sun9Aug

    Actual outcome: Bull · $3.78 at outcome

    SANA reported an EPS actual of -0.17, matching the estimate, with no significant guidance changes. The stock rallied due to positive pipeline progress and strategic partnerships announced during the earnings call, which signaled long-term growth potential. The price move aligned with the bull target as investors focused on the company's forward-looking developments rather than the neutral earnings report.

    Quarterly financial update and pipeline progress report.

  • Wed6May

    Actual outcome: Bull · $3.11 at outcome

    Sana Biotechnology reported Q1 2026 results alongside a strategic collaboration with Mayo Clinic for type 1 diabetes and positive preclinical data for its in vivo CAR T cell therapy SG293. Furthermore, the company resolved financing clarity by raising approximately $69 million through its ATM facility. Although the stock experienced a pullback from its event-date highs, these clinical and capital updates kept shares trading well above the $2.30 bull target.

    On 2026-05-06, Sana is expected to report Q1 2026 results and update its runway post-raise, with the stock likely near $1.9 into the print and resolving toward $2.30 if cash duration and spend discipline surprise positively, or $1.5 if burn remains high and guidance underwhelms by 2026-05-20.

  • Wed15Apr

    Actual outcome: Bull · $3.27 at outcome

    Sana successfully addressed its anticipated capital needs without resorting to the highly punitive dilution feared by the market. The execution of funding on constructive terms extended the company's runway and alleviated shareholder overhang, driving the stock well above the bull target to $3.50 by the run date.

    Around 2026-04-15, Sana may execute a dilutive capital raise to extend runway, with the stock likely trading near $3.15 into the event and resolving toward either $2.6 in a constructive deal scenario or $1.9 if terms are more punitive or signal funding stress by 2026-05-01.

  • Mon16Mar

    Actual outcome: Bear · $3.12 at outcome

    Sana Biotechnology shares fell 4.6% following its expected Q4 financial update and a subsequent presentation at the Citizens Life Sciences Conference. In the absence of reassuring cash runway details or positive clinical catalysts from these updates, investor sentiment skewed negative, driving a modest sell-off.

    Disclosure of final 2025 cash burn and explicit guidance on 'going concern' status given the current $71M cash balance.